Two-Layered Dissolving Microneedles for Percutaneous Delivery of Peptide/Protein Drugs in Rats

被引:139
作者
Fukushima, Keizo [1 ]
Ise, Ayaka [1 ]
Morita, Hiromi [1 ]
Hasegawa, Ryo [1 ]
Ito, Yukako [1 ]
Sugioka, Nobuyuki [1 ]
Takada, Kanji [1 ]
机构
[1] Kyoto Pharmaceut Univ, Dept Pharmacokinet, Yamashina Ku, Kyoto 6078412, Japan
关键词
bioavailability; desmopressin (DDAVP); dissolving microneedles; recombinant human growth hormone (rhGH); transdermal delivery; HUMAN GROWTH-HORMONE; CHONDROITIN SULFATE PROTEOGLYCAN; SOLID DISPERSION; INTESTINAL-ABSORPTION; TRANSDERMAL DELIVERY; ORAL BIOAVAILABILITY; ENTERAL ABSORPTION; RECTAL ABSORPTION; HUMAN SKIN; INSULIN;
D O I
10.1007/s11095-010-0097-7
中图分类号
O6 [化学];
学科分类号
070301 [无机化学];
摘要
Purpose Feasibility study of two-layered dissolving microneedles for percutaneous delivery of peptide/proteins using recombinant human growth hormone (rhGH) and desmopressin (DDAVP). Methods Two-layered dissolving microneedles were administered percutaneously to the rat skin. Plasma rhGH and DDAVP concentrations were measured by EIA and LC/MS/MS. In vivo dissolution and diffusion rates of drugs in the skin were studied using tracer dyes, lissamine green B (LG) for rhGH and evans blue (EB) for DDAVP. Diffusion of drugs vertically into the skin was studied using FITC-dextran (MW=20 kDa)-loaded dissolving microneedles. Stability experiments were performed at -80 degrees C and 4 degrees C. Results The absorption half-lives, t(1/2a), of rhGH and DDAVP from dissolving microneedles were 23.7 +/- 4.3-28.9 +/- 5.2 and 14.4 +/- 2.9-14.1 +/- 1.1 min; the extents of bioavailability were 72.8 +/- 4.2-89.9 +/- 10.0% and 90.0 +/- 15.4-93.1 +/- 10.3%, respectively. LG and EB disappeared from the administered site within 2 h and 3 h after administration. Five green fluorescein spots were detected at 15 s and enlarged transversally at 30 s. FITC-dextran was delivered into the microcapillaries at 5 min and 10 min. The rhGH and DDAVP were stable in dissolving microneedles for one month at -80 degrees C and 4 degrees C. Conclusions Results suggest that the two-layered dissolving microneedles are useful as an immediate-release transdermal DDS for peptide/protein drugs.
引用
收藏
页码:7 / 21
页数:15
相关论文
共 71 条
[1]
Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients [J].
Agerso, H ;
Larsen, LS ;
Riis, A ;
Lövgren, U ;
Karlsson, MO ;
Senderovitz, T .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (04) :352-358
[2]
AMINO Y, 1988, CHEM PHARM BULL, V36, P4426
[3]
Micro-scale devices for transdermal drug delivery [J].
Arora, Anubhav ;
Prausnitz, Mark R. ;
Mitragotri, Samir .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 364 (02) :227-236
[4]
A strikingly constant ratio exists between Langerhans cells and other epidermal cells in human skin.: A stereologic study using the optical disector method and the confocal laser scanning microscope [J].
Bauer, J ;
Bahmer, FA ;
Wörl, J ;
Neuhuber, W ;
Schuler, G ;
Fartasch, M .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 116 (02) :313-318
[5]
Caspers PJ, 2000, J RAMAN SPECTROSC, V31, P813, DOI 10.1002/1097-4555(200008/09)31:8/9<813::AID-JRS573>3.0.CO
[6]
2-7
[7]
Lipid vesicles and other colloids as drug carriers on the skin [J].
Cevc, G .
ADVANCED DRUG DELIVERY REVIEWS, 2004, 56 (05) :675-711
[8]
Microfabricated silicon microneedles for nonviral cutaneous gene delivery [J].
Chabri, F ;
Bouris, K ;
Jones, T ;
Barrow, D ;
Hann, A ;
Allender, C ;
Brain, K ;
Birchall, J .
BRITISH JOURNAL OF DERMATOLOGY, 2004, 150 (05) :869-877
[9]
Intranasal delivery of recombinant human growth hormone (somatropin) in sheep using chitosan-based powder formulations [J].
Cheng, YH ;
Dyer, AM ;
Jabbal-Gill, I ;
Hinchcliffe, M ;
Nankervis, R ;
Smith, A ;
Watts, P .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 26 (01) :9-15
[10]
Transdermal delivery of desmopressin using a coated microneedle array patch system [J].
Cormier, M ;
Johnson, B ;
Ameri, M ;
Nyam, K ;
Libiran, L ;
Zhang, DD ;
Daddona, P .
JOURNAL OF CONTROLLED RELEASE, 2004, 97 (03) :503-511